Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients
This study is being done to determine if using the Paxman Scalp Cooling System at temperatures lower than the current standard is a safe and tolerable approach to prevent hair loss in breast cancer patients receiving chemotherapy.
Breast Cancer|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III
DEVICE: PAXMAN Scalp Cooler
Safety as assessed by CTCAE, Safety will be determined by toxicity assessment according to CTCAE, Up to 44 weeks from the start of treatment
This study is being done to determine if using the Paxman Scalp Cooling System at temperatures lower than the current standard is a safe and tolerable approach to prevent hair loss in breast cancer patients receiving chemotherapy.